Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50

B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously

H.C. Wainwright downgraded Geron from Buy to Neutral

H.C. Wainwright initiated coverage of Geron with a rating of Buy and set a new price target of $8.00

Scotiabank initiated coverage of Geron with a rating of Sector Outperform

Leerink Partners initiated coverage of Geron with a rating of Outperform and set a new price target of $7.00

Robert W. Baird downgraded Geron from Outperform to Neutral and set a new price target of $4.50

TD Cowen initiated coverage of Geron with a rating of Buy and set a new price target of $10.00

Needham reiterated coverage of Geron with a rating of Buy and set a new price target of $5.00 from $4.00 previously

Goldman upgraded Geron from Neutral to Buy and set a new price target of $4.00

10-Q - GERON CORP (0000886744) (Filer)

8-K - GERON CORP (0000886744) (Filer)

DEFA14A - GERON CORP (0000886744) (Filer)

DEF 14A - GERON CORP (0000886744) (Filer)

8-K/A - GERON CORP (0000886744) (Filer)

8-K - GERON CORP (0000886744) (Filer)

8-K - GERON CORP (0000886744) (Filer)

SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)

8-K - GERON CORP (0000886744) (Filer)

10-Q - GERON CORP (0000886744) (Filer)

4 - GERON CORP (0000886744) (Issuer)

4 - GERON CORP (0000886744) (Issuer)

4 - GERON CORP (0000886744) (Issuer)

Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026 Company to host conference call and webcast today, May 7 at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial

Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,551,000 shares of its common stock, consisting of stock options to purchase an aggregate of 1,034,000 shares of common stock and restricted stock units ("RSUs") representing an aggregate of 517,000 shares of common stock, to twelve newly hired employees as an inducement material to their acceptance of employment with the Company. The stock options and RSUs were granted on April 17, 2025. The stock options have an exercise price of $1.27 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year

Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and business highlights before the market opens on Wednesday, May 7, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website for 30 days. Participants m

Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 225,000 shares of its common stock, consisting of stock options to purchase an aggregate of 150,000 shares of common stock and restricted stock units ("RSUs") representing an aggregate of 75,000 shares of common stock, to three newly hired employees as an inducement material to their acceptance of employment with the Company. The stock options and RSUs were granted on March 17, 2025. The stock options have an exercise price of $1.74 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year term

Approval across ESA ineligible and ESA relapsed/refractory non-del 5q patients with transfusion-dependent anemia due to LR-MDS, regardless of ring sideroblast (RS) status RYTELO is the first and only telomerase inhibitor approved in the U.S. and Europe Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has granted marketing authorization for RYTELO® (imetelstat) as a monotherapy for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myelodysplastic syndromes (lower-risk MDS or LR-MDS) wi

Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development

Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated tre

Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care Conference Monday, March 3rd at 3:10pm ET (Boston, MA) Leerink Global Healthcare Conference Monday, March 10th 3:00pm ET (Miami, FL) Barclays 27th Annual Global Healthcare Conference Tuesday, March 11th 10:30am ET (Miami, FL) A live webcast of each fireside chat will be available through the Investors & Media section of the Geron's website under Events. A replay of the webcast will be archived and available on Geron's website for 3

Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 180,000 shares of its common stock, consisting of stock options to purchase an aggregate of 120,000 shares of common stock and restricted stock units ("RSUs") representing an aggregate of 60,000 shares of common stock, to two newly hired employees as an inducement material to their acceptance of employment with the Company. The stock options and RSUs were granted on February 18, 2025. The stock options have an exercise price of $2.63 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year term

Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website f

SC 13G/A - GERON CORP (0000886744) (Subject)

SC 13G/A - GERON CORP (0000886744) (Subject)

SC 13G - GERON CORP (0000886744) (Subject)

SC 13G/A - GERON CORP (0000886744) (Subject)

SC 13G/A - GERON CORP (0000886744) (Subject)

SC 13G - GERON CORP (0000886744) (Subject)

SC 13G/A - GERON CORP (0000886744) (Subject)

SC 13G/A - GERON CORP (0000886744) (Subject)

SC 13D/A - GERON CORP (0000886744) (Subject)

SC 13G - GERON CORP (0000886744) (Subject)

Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development

Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving innovative medical and scientific strategies that support RYTELO™ commercially and sustain important research and development opportunities for Geron. Dr. Eid has more than two decades of medical affairs, clinical development, and drug life-cy

Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegler has more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations. "Jim brings to Geron an impressive track record of operationa

For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company's Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board level. "Gaurav brings extensive strategic leadership to Geron, and we believe his demonstrated track record in both corporate strategy and capital formation will add tremendous value as we look forward to a potential commercial launch in 2024

Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson's appointment follows the retirement of Olivia Bloom, Geron's incumbent CFO, also effective September 25, 2023. Ms. Bloom's retirement brings to a close a remarkable career of nearly 30 years on Geron's finance team, including serving the last twelve years as CFO. "On behalf of the Board and our entire team, I would first like to express our deep appreciation and admiration for the countless contributions Olivia has made during her extraor

Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ

Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John F. McDonald as an independent member of its Board of Directors, effective September 7, 2022. "With his three decades in the biopharmaceutical industry across business development and investment and corporate strategy, John is a highly respected and seasoned R&D executive with valuable pharmaceutical and biotechnology experience. We enthusiastically welcome him to the Board," said John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer. "We believe John's expertise will add commercial and strategic perspectives in guiding our objectives to advance imetelstat

Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Faye Feller, M.D., to Executive Vice President and Chief Medical Officer, effective July 9, 2022. Dr. Feller will succeed Dr. Aleksandra Rizo, Geronʻs current Chief Medical Officer, who will transition to a consultant role to the Company, as Senior Medical and Regulatory Advisor. Outside of Geron, Dr. Rizo has accepted a leadership position with a privately held discovery and preclinical-stage platform biotechnology company. Dr. Feller has been instrumental in the design, execution and management of the imetelstat development program for the past seven years, starting when s

Geron Corporation (NASDAQ:GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer. "Ed Koval's business development expertise, extensive industry network and successful track record in corporate deal-making further strengthens our executive team," said John A. Scarlett, M.D., Chairman and Chief Executive Officer. "With top-line results from our IMerge Phase 3 trial in lower risk MDS expected 13 months from now, and an interim analysis of our ongoing IMpactMF Phase 3 trial in refractory myelofibrosis expecte